Gene editing, particularly through the use of the revolutionary CRISPR-Cas9 tool, can modify the DNA of organisms directly, allowing scientists to alter genetic material at precise locations in the genome. The technology, which has aroused substantial interest amongst biotech companies, holds significant potential to transform health care by offering treatments for genetic disorders through precise genetic corrections. However, concerns over off-target effects, efficacy and ethical issues surrounding human germline editing remain prevalent. Continue reading